Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

62.60 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Beyond The Numbers: 11 Analysts Discuss Tempus AI Stock
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
From Tempus AI, Inc.
Via Business Wire
Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025
From Tempus AI, Inc.
Via Business Wire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (and Sold)
Via The Motley Fool
Earnings Scheduled For May 6, 2025
Via Benzinga
Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:POAI),(NYSE:TDOC),(NASDAQ:GEHC) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies
From FN Media Group LLC
Via GlobeNewswire
MarketBeat Week in Review – 05/05 - 05/09
Equities turned bullish this week on renewed hopes for progress in trade deals; next week's inflation readings could be a market mover 
Via MarketBeat
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Economy Interest Rates
Investing in CoreWeave: Key Insights on the NVIDIA‑Backed AI IPO
CoreWeave is arguably the most talked-about new stock in 2025. What is to make of this AI cloud infrastructure firm with a significant investment from NVIDIA? 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus AI Stock: Time to Double Down or Cut and Run?
Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside potential. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Strengthens AI Chip Holdings With Nvidia And AMD Purchases, Reduces Palantir Position By Another $38.8 Million
On Wednesday, May 7, 2025, Cathie Wood's Ark Invest Pours $24M Into Nvidia and AMD While Offloading $38.8M in Palantir Shares. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Deals
Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ contract value. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Warren Buffett Falls Behind Nancy Pelosi In Stock Market Returns Over The Last 11 Years: Here's What Data Shows
Nancy Pelosi's investments over 11 years have outperformed the 'Oracle of Omaha', Warren Buffett's Berkshire Hathaway. 
Via Benzinga
Cathie Wood-Backed Tempus AI Says Pharma Contracts Solid Despite Biotech Funding Challenges, Tariff Pressures
Tempus AI reassured investors that its major pharma contracts remain strong despite funding and tariff pressures. 
Via Benzinga
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model
The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus AI Q1 Earnings: Revenue Beat, EPS Beat, Raised FY Guidance, Shares Surge
Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision medicine and patient care company reports a first-quarter adjusted loss of 24... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus Reports First Quarter 2025 Results
From Tempus AI, Inc.
Via Business Wire
Tempus AI (TEM) Stock Lower Ahead Of Q1 Earnings Report, Notetaker AI Debut
Tempus AI shares are trading lower by 1.3% Tuesday afternoon. The company will report its Q1 earnings after Tuesday's market close. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry
From Tempus AI, Inc.
Via Business Wire
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Jim Cramer: Sunrun Had 'Bad Couple Of Quarters,' ExlService Holdings Is 'Solid'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. because "it's going to be a great position." 
Via Benzinga
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
From Tempus AI, Inc.
Via Business Wire
Is This the Best Nancy Pelosi Stock to Buy After a 40% Pullback?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
From Tempus AI, Inc.
Via Business Wire
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
From FN Media Group LLC
Via GlobeNewswire
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
From Tempus AI, Inc.
Via Business Wire
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?
Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
From Tempus AI, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.